公开(公告)号：US20230210969A1

公开(公告)日：2023-07-06

申请号：US17938270

申请日：2022-10-05

Applicant: Nantomics LLC

Inventor： Stephen Charles Benz ,  Andrew Nguyen ,  Charles Joseph Vaske ,  John Zachary Sanborn

IPC: A61K39/00 ,  A61K47/68 ,  C07K14/47 ,  C12N5/0783 ,  G01N33/574 ,  C07K16/30 ,  C12N5/09 ,  C07K16/22

CPC classification number: A61K39/001102 ,  A61K47/6851 ,  C07K14/4702 ,  C12N5/0638 ,  C12N5/0646 ,  A61K39/001144 ,  G01N33/57407 ,  C07K16/30 ,  C12N5/0693 ,  C07K16/22 ,  A61K2039/812 ,  A61K2039/53 ,  A61K2039/505 ,  A61K2039/80 ,  C07K2319/60 ,  A61K2039/892 ,  C07K2317/34 ,  C07K2319/55

Abstract: Certain universal neoepitopes and cancer specific neoepitopes and methods therefor are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.

公开(公告)号：US20190216910A1

公开(公告)日：2019-07-18

申请号：US16263098

申请日：2019-01-31

Applicant: President and Fellows of Harvard College

Inventor： David J. Mooney ,  W. Aileen Li ,  Omar Abdel-Rahman Ali ,  Ting-Yu Shih

IPC: A61K39/00 ,  A61K39/39 ,  A61K47/02 ,  A61K47/34

CPC classification number: A61K39/001106 ,  A61K9/0019 ,  A61K9/5031 ,  A61K39/00119 ,  A61K39/39 ,  A61K47/02 ,  A61K47/34 ,  A61K2039/5154 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55522 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/6056 ,  A61K2039/812 ,  A61K2039/876 ,  A61P35/00

Abstract: The provided herein are methods and compositions for eliciting an immune response to an antigen, such as cancer and microbial antigens.

公开(公告)号：US20230414735A1

公开(公告)日：2023-12-28

申请号：US18311158

申请日：2023-05-02

Applicant: BioNTech US Inc.

Inventor： Michael Steven Rooney

IPC: A61K39/00 ,  A61P35/04 ,  A61P35/00 ,  A61K45/06 ,  C07K14/47 ,  C12N9/00 ,  C07K14/705 ,  C07K4/12

CPC classification number: A61K39/001164 ,  A61P35/04 ,  A61P35/00 ,  A61K39/001103 ,  A61K39/001151 ,  A61K39/001108 ,  A61K39/001107 ,  A61K39/001163 ,  A61K39/001106 ,  A61K39/001162 ,  A61K39/001104 ,  A61K39/0011 ,  A61K45/06 ,  C07K14/4748 ,  A61K39/001102 ,  A61K39/001134 ,  A61K39/001154 ,  C12N9/00 ,  C07K14/47 ,  C07K14/705 ,  C07K4/12 ,  A61K39/001152 ,  A61K2039/812 ,  A61K2039/836 ,  A61K2039/5158 ,  A61K2039/82 ,  A61K2039/505 ,  A61K2039/828 ,  A61K2039/804 ,  A61K38/00

Abstract: The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

公开(公告)号：US20230233656A1

公开(公告)日：2023-07-27

申请号：US18012432

申请日：2021-06-25

Applicant: National Breast Cancer Coalition

Inventor： Keith L. Knutson

IPC: A61K39/00 ,  C12N15/86

CPC classification number: A61K39/001106 ,  A61K39/00115 ,  A61K39/00117 ,  A61K39/001186 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/812 ,  C12N2710/24143

Abstract: The invention relates to vaccines for breast cancer therapy. The invention also relates to methods of preventing and treating breast cancer using a breast cancer vaccine.

公开(公告)号：US20170253633A1

公开(公告)日：2017-09-07

申请号：US15445461

申请日：2017-02-28

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K7/08 ,  C07K16/18 ,  G01N33/68 ,  A61K35/17 ,  A61K39/00 ,  C12N15/115 ,  C07K7/06 ,  C07K14/725

CPC classification number: C07K7/08 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/80 ,  A61K2039/804 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/844 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/876 ,  A61K2039/884 ,  A61K2039/892 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K2319/00 ,  C12N15/115 ,  C12N2310/16 ,  G01N33/6893 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12103984B2

公开(公告)日：2024-10-01

申请号：US17333945

申请日：2021-05-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K16/18 ,  A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C12N15/115 ,  G01N33/68 ,  A61K35/12

CPC classification number: C07K7/08 ,  A61K35/17 ,  A61K39/0011 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C12N15/115 ,  G01N33/6893 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/80 ,  A61K2039/804 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/844 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/876 ,  A61K2039/884 ,  A61K2039/892 ,  C07K2319/00 ,  C12N2310/16 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12064475B2

公开(公告)日：2024-08-20

申请号：US18170994

申请日：2023-02-17

Applicant: Think Therapeutics, Inc.

Inventor： David Kenneth Gifford ,  Brandon Carter

IPC: A61K39/00 ,  A61K38/00 ,  A61K38/04 ,  A61K38/08 ,  A61K38/10 ,  A61P35/00 ,  C07K5/00 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K16/00 ,  C07K17/00 ,  A61K48/00

CPC classification number: A61K39/00116 ,  A61K38/08 ,  A61K38/10 ,  A61K39/001152 ,  A61K39/001158 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K48/00

Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

公开(公告)号：US20240083947A1

公开(公告)日：2024-03-14

申请号：US18345700

申请日：2023-06-30

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C12N15/115 ,  G01N33/68

CPC classification number: C07K7/08 ,  A61K35/17 ,  A61K39/0011 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C12N15/115 ,  G01N33/6893 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/804 ,  A61K2039/812 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/892

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230210971A1

公开(公告)日：2023-07-06

申请号：US17889715

申请日：2022-08-17

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Huang-Ge Zhang

IPC: A61K39/00 ,  A61K9/00 ,  A61K31/05 ,  A61K31/513 ,  A61K33/243 ,  A61K31/203 ,  A61P35/00 ,  A61P35/04 ,  A61K31/12 ,  C12N15/113 ,  A61K31/704 ,  A61K9/127 ,  A61K39/39 ,  A61K31/475 ,  A61K38/12 ,  A61K31/337 ,  A61K31/353

CPC classification number: A61K39/0012 ,  A61K9/0056 ,  A61K31/05 ,  A61K31/513 ,  A61K33/243 ,  A61K31/203 ,  A61P35/00 ,  A61P35/04 ,  A61K31/12 ,  C12N15/1135 ,  A61K39/001102 ,  A61K31/704 ,  A61K9/1277 ,  A61K39/39 ,  A61K31/475 ,  A61K38/12 ,  A61K31/337 ,  A61K31/353 ,  A61K2039/55 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  A61K2039/812 ,  A61K2039/6018

Abstract: Provided are compositions and methods for using the same. In some embodiments, the compositions include an EPELN encapsulating and/or having associated therewith an active agent and a plasma membrane derived from a tumor and/or cancer cell coating the EPELN. In some embodiments, the active agent is a therapeutic agent or an immune response modifier, and in some embodiments the plasma membrane has one or more tumor-associated and/or cancer-associated antigens. Also provided are methods for using the compositions for treating tumors and/or cancers, inducing anti-tumor and/or anti-cancer immune responses, activating antigen-presenting cells, targeting CD11c dendritic cells, and preventing or reducing metastasis.

公开(公告)号：US11673917B2

公开(公告)日：2023-06-13

申请号：US16671981

申请日：2019-11-01

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K7/08 ,  C07K16/18 ,  A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K7/06 ,  G01N33/68 ,  C12N15/115 ,  A61K35/17 ,  A61K35/12

CPC classification number: C07K7/08 ,  A61K35/17 ,  A61K39/0011 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C12N15/115 ,  G01N33/6893 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/80 ,  A61K2039/804 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/844 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/876 ,  A61K2039/884 ,  A61K2039/892 ,  C07K2319/00 ,  C12N2310/16 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.